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Abstract
Introduction Namibia has the highest burden and incidence of
hypertension in sub-Sahara Africa. Though non-adherence to
antihypertensive therapy is an important cardiovascular risk
factor, little is known about potential ways to improve adher-
ence in Namibia following universal access. The objective of
this study is to validate the Hill-Bone compliance scale and
determine the level and predictors of adherence to antihyper-
tensive treatment in primary health care settings in sub-urban
townships of Windhoek, Namibia.
Methods Reliability was determined by Cronbach’s alpha.
Principal component analysis (PCA) was used to assess con-
struct validity.
Results The PCA was consistent with the three constructs
for 12 items, explaining 24.1, 16.7 and 10.8% of the
variance. Cronbach’s alpha was 0.695. None of the 120
patients had perfect adherence to antihypertensive therapy,
and less than half had acceptable levels of adherence
(≥ 80%). The mean adherence level was 76.7 ± 8.1%.
Three quarters of patients ever missed their scheduled
clinic appointment. Having a family support system
(OR = 5.4, 95% CI 1.687–27.6, p = 0.045) and attendance
of follow-up visits (OR = 3.1, 95% CI 1.1–8.7, p = 0.03)
were significant predictors of adherence. Having HIV/
AIDs did not lower adherence.
Conclusions The modified Namibian version of the Hill-
Bone scale is reliable and valid for assessing adherence to
antihypertensives in Namibia. There is sub-optimal adherence
to antihypertensive therapy among primary health cares in
Namibia. This needs standardized systems to strengthen
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adherence monitoring as well as investigation of other factors
including transport to take full advantage of universal access.
Keywords Adherence . Hypertension . Namibia . Primary
health care . Universal access
Introduction
Cardiovascular diseases (CVD) remain a significant health
problem in lower and middle income countries (LMICs) in-
cluding Namibia [1, 2]. In 2001, three out of four patients or
more with hypertension lived in LMICs particularly in the
Africa region [3–5]. In 2008, an estimated 17 million people
died from CVD globally [1, 6, 7]. In the same year, more than
half of CVD-related deaths (9.4 million) were due to hyper-
tension [6]. The majority were premature due to uncontrolled
blood pressure [8].
In Namibia, CVD accounted for 21% of annual deaths in
2012 [9], with the prevalence of hypertension among adults
aged between 35 and 64 at between 44 and 45% [9, 10],
appreciably higher than the pooled prevalence rates of 30%
in sub-Sahara Africa [2]. However, among patients with hy-
pertension in LMICs, only between 33 and 66% of them are
currently receiving antihypertensive medicines [4]. This prev-
alence and mortality level demands strengthening and scale-
up of health care systems, including primary health care facil-
ities in LMICs, to prevent, manage, and control hypertension,
to improve health outcomes in the future [1, 6, 11]. As a result,
it helps achieve sustainable development goal (SDG) 3.4,
aiming to reduce premature mortal i ty from non-
communicable diseases (NCDs) by one third from current
levels by 2030 [12]. This includes strategies to optimize ad-
herence to antihypertensive therapy [6, 13, 14], although this
may not always be the case [15], as well as enhance access to
affordable medicines to treat NCDs including hypertension by
80% [12].
To address this considerable and growing public health
problem, primary health care (PHC) centres and policies in
Namibia now provide for universal access to essential antihy-
pertensive medicines as well as other aspects of care at no cost
[16–19]. PHC facilities in Namibia are strategically located
among under privileged communities and play a critical role
in the access to care for patients with hypertension. Universal
access reduces a financial barrier to accessing antihyperten-
sivemedicines, which can be a concern in LMICwith high co-
payment levels [2, 20]. However, this raises the question on
the extent of other factors involved in subsequent poor levels
of adherence to antihypertensive medicines in LMICs if this
still occurs following universal access.
Consequently, the aim of this study is to determine the
levels and predictors of compliance to antihypertensive med-
icines among patients receiving care at PHC facilities in four
sub-urban townships in the capital city, Windhoek. In addi-
tion, this study also aims to validate the Hill-Bone compliance
scale. The findings will be used to suggest future policies in
Namibia and wider to improve the management of hyperten-
sive patients.
Methods
Study Design
A descriptive cross-sectional observational study was under-
taken. The study included patients initiated on antihyperten-
sive medication at public PHCs in four sub-urban townships
of Windhoek. There are a total of seven PHCs in Windhoek;
however, only four are located in peri-urban settings similar to
other situations in sub-Sahara regions. Those in the central
business district of Windhoek were excluded due to their cos-
mopolitan patient population. The chosen PHCs are based in
Okuryangava, Otjomuise, Donkerhoek and Hakahana. These
four PHCs are the only public outpatient clinics in these town-
ships that provide primary health care services, and this is
mainly to low socioeconomic groups, the majority of whom
do not have medical insurance cover [21]. In Namibia, anti-
hypertensive therapy is initiated at hospital level, with patients
subsequently accessing free follow-up care and medication
refills at PHCs and other centers.
The main outcome measure was the proportion of patients
with adherence levels to antihypertensive therapy ≥ 80% on
the Hill-Bone blood pressure scale, in line with previous pub-
lications [6, 22]. The secondary outcome measure was predic-
tors of adherence to antihypertensive medication.
Patients were selected using a systematic sampling method
based on the daily attendance registers. The target sample was
30 patients per PHC facility as recommended by the WHO/
INRUD method for measuring medicine use in the community
[23]. The study included all patients who had confirmed diag-
nosis of hypertension, had completed at least one cycle
(6 months) of antihypertensive medication refill at the PHC,
were aged more than 18 years, were able to recognize and tell
apart their antihypertensivemedicines from any other dailymed-
icines and had given written informed consent to participate in
the study.
Out of a total of 185 patients selected, 143 patients met
the eligibility criteria, with 42 patients not routinely
(> 6 months) receiving antihypertensive refills at the four
PHCs under investigation. The study excluded 23 more
patients. Seven did not consent to participate, four were
too ill to participate in the interviews, three had incomplete
or incoherent records regarding their clinical characteris-
tics and antihypertensive therapies in their health records
(passports) and a further nine were due to systematic se-
lection of patients to meet the sample size (Fig. 1).
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Validation of the Hill-Bone Scale and Data Collection
The reliability of the Namibian version of the Hill-Bone scale
was determined by the Cronbach’s alpha. Principal component
analysis (PCA) was used to assess construct validity. The ques-
tionnaire, after taking details of the patient characteristics and
their medical history (Sections A and B), was structured accord-
ing to the Hill-Bone compliance to high blood pressure therapy
scale (HBCHTS) [24, 25]. The scale assesses patient behaviours
for three important behavioural domains of high blood pressure
treatment, which are reducing sodium intake, appointment keep-
ing and medication taking [24]. The HBCHTS has been validat-
ed in a number of countries including among black Africans in
South Africa, a country with similar primary health care centres
and cultures to Namibia [25–28]. The HBCHTS scale was pre-
ferred over the Morisky Medication Adherence Scale (MMAS)
methods in this study due to the variety of items used to assess
adherence. This is because theHBCHTS questionnaire is ‘based
on the Morisky scale and is specific to antihypertensive therapy
and assesses items pertaining to lifestyle modification in the
setting of hypertension’ [24].
Data Collection
The data was collected from 11 July until 3 August 2016 by the
researchers led by SN, MM and DK. On the day of data collec-
tion, every other second patient on the daily attendance register
was interviewed using a pre-tested structured questionnaire
(Appendix A). The first question before the formal questions
started was whether the patient was currently taking any medi-
cation for hypertension. If the answer was no, the interview was
stopped and the patient was excluded from the study. Interviews
were conducted in Afrikaans and in Oshiwambo, the most com-
monly spoken local languages in Namibia.
The interview question items of the HBCHTS were
adapted to Namibia’s situation and used to test for the level
of adherence to antihypertensive medication [24, 26]. The
level and predictors of adherence to antihypertensive medica-
tion were analysed using quantitative analysis in SPSS soft-
ware version 22.
The HBCHTS scale has 14 question items with a 4-point
Likert response format around four response categories to
each question. These were the following: all the time—1
point, most of time—2 points, sometimes—3 points and none
of the times—4 points. Consequently, a maximum of 4 points
where 4 indicates the poorest compliance and 1 indicates the
best compliance. The scores were adjusted by the percentage
of patients in each category to derive the mean and standard
deviation for each of the 14 items (maximum of 4). The lower
the mean score, the better the compliance with medication,
appointment keeping and avoidance of salty and fast foods.
Consequently, replies to questions with a mean score > 2 were
indicative of poor compliance.
The item and factor analyses showed reliability for the final
12 items chosen (Table 2). After adding the points of all 12
items of the modified scale, the total score should range from
12 to 48 points. Perfect adherence is equivalent to 12 points on
the HBCHTS scale. The percentage adherence level per pa-
tient was subsequently calculated from the HBCHTS scores
using the formula %adherence ¼ 48−Hill–Bone scoreð Þ100
36
. The
denominator (36) is the range of HBCHTS scores (48 − 12).
Adherence to antihypertensive therapy was categorized as
42 patients were not
selected due to < 6
months on therapy
Hypertensive patients – a total of 185 patients
were accessible during the study period
143
Patients
120
Patients included in the sample
185
Hypertensive Patients
23 patients were excluded
7 did not consent
4 too ill to participate
3 incomplete records
9 systematic sampling
Fig. 1 Flow chart for patient
sample selection
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perfect (100%), acceptable ≥ 80%, and non-adherence if less
than 80% in line with previous studies [6, 22, 29, 30]. Chi-
square test was used to assess for associations between adher-
ence and individual’s characteristics. A multivariate logistic
regression analysis was performed to adjust for confounders,
and the results were presented as odds ratio (OR) and 95%
confidence interval.
Ethics
The study was approved by the research and ethics com-
mittee of the Faculty of Health Sciences, UNAM and the
Ministry of Health and Social Services (MoHSS). All pa-
tients who participated in the study gave written informed
consent. The management of the four PHCs, i.e.
Okuryangava HC, Ot jomuise , Donkerhoek and
Hakahana, approved the study. In order to maintain con-
fidentiality, questionnaires were coded and no patient spe-
cific identifiers such as names and hospital numbers were
collected.
Results
Bivariate Analysis of Sociodemographic and Clinical
Characteristics
A total of 120 patients with hypertension (i.e. responded
‘yes’ to the first question—Appendix A) completed the
s tudy (100% response ra te ) ; the mean age was
47.3 ± 11.1 years. The majority of the respondents were
female, attained at least primary level education, were un-
employed and not married (Table 1). Approximately four
out of every ten patients had at least one other chronic co-
morbidity in addition to hypertension, the most common
being HIV/AIDS (n = 31–25.8%).
Most patients had adequate supplies of medicines to
last them until the next PHC visit (Table 1). Three quar-
ters of the patients (75%) have ever missed their sched-
uled clinic appointment (Table 1). The main reasons were
being work commitments (n = 54, 60%) and/or feeling ill
(n = 12, 13%), forgetting the appointment day (n = 11,
12%) or lacking of transport to the health facility (n = 14,
15%). The majority of patients (n = 100, 83.3%) reported
receiving adequate information from health care providers
on how to take their medication. However, over half of
the patients were not knowledgeable of the consequences
of hypertension and non-adherence to medication
(Table 1). Most patients (n = 94, 78.3%) received support
from friends and/or relatives in adhering to treatment and
attending clinic appointments (the form of support includ-
ed reminders to attend clinic appointments and to take
medicines at the prescribed time).
Reliability and Validity of the Namibian Version
of the Hill-Bone Compliance Scale
The reliability and construct validity of the Namibian Hill-
Bone compliance scale was determined using item and factor
analysis. A modified scale consisting of 12 items (after exclu-
sion of items 6 and 12 from the original scale) demonstrated
acceptable internal consistency with a standardized Cronbach
α of 0.70 (0.695), and item-total correlations all (> 0.31), with
mean inter-item correlation of 0.16. The initial principal com-
ponent analysis with a yielded four constructs of the Namibian
version of the Hill-Bone compliance scale. A forced three
structures with a KMO of 0.634 and a significant Bartlett’s
test of sphericity (p < 0.001) was consistent with the three
constructs of the Hill-Bone scale with Eigen values and vari-
ances of 2.9 (24.1%) for medication taking, 2.0 (16.7%) for
salt taking and 1.3 (10.8%) for appointment keeping (Table 2).
Compliance to High Blood Pressure Therapy According
to the Hill-Bone Compliance Scale
The mean HBCHTS score for the 12 items on the 4-Likert
point scale was 1.7 ± 0.2, this ranged from 1.01 to 2.3 (57.5%)
by question item (Table 2). Most question items (10/12,
71.4%) had a mean score < 2. Only one item had a perfect
mean score of 1, which was ever missing taking medication
because of carelessness. The three items that scored poorly
(mean score > 2) included items 3, 4 and 5 that assess the
domain of salt intake and eating salty foods (2.2/4), using
spices and additional salt on food (2.3/4) and eating fast food
(2.1/4) (Table 2). Overall, no patients had perfect HBCHTS
total score of 12. The mean HBCHTS score for the 12-item
modified scale among the patients was 20.4 ± 2.9 out of a
possible 48 points, with the IQR of 18–23 points.
According to the results of the bivariate analysis (Table 1),
the following factors were significantly associated with good
adherence to antihypertensive therapy (adherence ≥ 80%): (i)
attendance to follow-up visits (p = 0.008), (ii) a patient’s age
of less than 40 years (p = 0.025), (iii) having a treatment
support buddy (p = 0.024) and (iv) never having missed a
clinic appointment (p < 0.001). There was a negative correla-
tion between patients’ ages and adherence to antihypertensive
medication (Pearson’s r = −1.28, p = 0.163).
Therewas no association between patients’sociodemographic
characteristics such as sex, employment status, education level
and adherence to antihypertensive medication (p > 0.05) in the
bivariate analysis (Table 1). There was also no association be-
tween adherence and any chronic co-morbidity and between
adherence and HIV/AIDS specifically.
The mean adherence level was 76.7 ± 8.1% with an IQR of
69.4–83.3% (Fig. 2). None of the patients had perfect adherence,
and less thanhalfof thepatients -42.5%(50/120) -hadacceptable
levels of adherence to antihypertensive therapy, that is ≥ 80%.
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Adherence rates varied among the PHC facilities with half
of the clinics having a mean adherence ≥ 80% threshold.
There was an association between the PHC clinic attended
and adherence rates (p = 0.109) (Table 1; Fig. 3).
Table 1 Bivariate analysis of characteristics of respondents and adherence (n = 120)
Characteristic Total (%) Adherence level Crude OR (95% CI) p value
≥ 80 (%) < 80 (%)
Total 120 51 (42.5) 69 (57.5) 0.201
Distance of PHC from state hospital
< 3 km 60 (50) 21 (35) 39 (65) 0.5 (0.3, 1.1) 0.097
> 3 km 60 (50) 30 (50) 30 (50) 1
PHC facility
Okuryangava 30 (25) 8 (26.7) 22 (73.3) 2.1 (0.7, 6.2) 0.229
Otjomuise 30 (25) 15 (50) 15 (50) 0.8 (0.3, 2.1) 0.179
Hakahana 30 (25) 15 (50) 15 (50) 0.8 (0.3, 2.1) 0.605
Donkerhoek 30 (25) 13 (43.3) 17 (56.7) 1 0.605
Age categories (years)
< 40 years 30 (33.3) 18 (60.0) 12 (40.0) 2.6 (1.1, 6.0) 0.025*
> 40 years 90 (66.7) 33 (36.7) 57 (63.3) 1
Patient’s sex
Male 51 (42.5) 20 (39.2) 31 (60.8) 0.8 (0.4, 1.6) 0.532
Female 69 (57.5) 31 (44.9) 38 (55.1) 1
Employment status
Employed 53 (44.2) 20 (37.7) 33 (62.3) 0.7 (0.3, 1.5) 0.348
Unemployed 67 (55.8) 31 (46.3) 36 (53.7) 1
Education level
At least primary 94 (78.3) 41 (43.6) 53 (56.4) 1.2 (0.5, 3.0) 0.638
No education 26 (21.7) 10 (38.5) 16 (61.5) 1
Marital status
Single 69 (57.5) 27 (39.1) 42 (60.9) 0.7 (0.3, 1.5) 0.385
Espoused 51 (41.5) 24 (47.1) 27 (52.9) 1
Years with hypertension
< 10 years 87 (72.5) 39 (44.8) 48 (55.2) 1.4 (0.6, 3.2) 0.402
> 10 years 33 (27.5) 12 (36.4) 21 (63.6) 1
Chronic co-morbidity
Yes 49 (40.8) 19 (38.8) 30 (61.2) 0.8 (0.4, 1.6) 0.493
No 71 (59.2) 32 (45.1) 39 (54.9)
HIV infection
Yes 31 (25.8) 12 (38.79) 19 (61.3) 0.8 (0.4, 1.9) 0.620
No 89 (74.2) 39 (43.8) 50 (56.2) 1
Has a treatment support buddy
Yes 94 (78.3) 45 (47.9) 49 (52.1) 3.1 (1.1, 8.3) 0.024*
No 26 (21.7) 6 (23.1) 20 (76.9) 1
Support buddy on clinic visits
Yes 94 (78.3) 37 (44.6) 46 (55.4) 1.3 (0.6, 2.9) 0.490
No 26 (21.7) 14 (37.8) 23 (62.2) 1
Sufficient medication refills on last visit
Yes 101 (84) 43 (42.6) 58 (57.4) 1.0 (0.4, 2.8) 0.970
No 19 (16) 8 (42.1) 11 (57.9) 1
Informed about medicine
Well informed 100 (83) 42 (42) 58 (58) 0.9 (0.3, 2.3) 0.804
Not informed 20 (17) 9 (45) 11 (55) 1
Knows complications
Knowledgeable 49 (40.8) 19 (38.8) 30 (61.2) 0.8 (0.4, 1.6) 0.493
Not knowledgeable 71 (59.2) 32 (45.1) 39 (54.9) 1
Attend follow-up visits
Always 30 (25) 19 (63.3) 11 (36.7) 3.1 (1.3, 7.4) 0.008*
Sometimes 90 (75) 32 (35.6) 58 (64.4) 1
Missed clinic appointment
Never 46 (25) 31 (67.4) 15 (32.6) 5.5 (2.5, 12.4) 0.000*
Ever 74 (75) 20 (27.0) 54 (73.0) 1
*Significant p < 0.05-y Pearson chi-squared test. Co-morbidities are any other diseases other than hypertension
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Table 2 Validity of the Namibian version of Hill-Bone compliance scale
Item Mean score (±SD) Sub-scales (principal component analysis)
How often? Factor 1
(medication
taking)
Factor 2
(salt taking)
Factor 3
(appointment
keeping)
Item 1: do you forget to take your hypertension medicine 1.5 ± 0.6 0.511
Item 2: do you decide not to take your hypertension
medicine
1.2 ± 0.4 0.473
Item 3: do you eat salty food 2.2 ± 0.8 − 0.934
Item 4: do you put salt on your food before you eat it 2.3 ± 0.8 − 0.935
Item 5: do you eat fast food (Kentucky Fried Chicken (KFC),
fat cook, fish and chips)
2.1 ± 0.8 − 0.737
Item 7: do you miss scheduled appointments 1.8 ± 0.6 0.523
Item 8: do you leave the dispensary before
obtaining your prescribed pills
1.6 ± 0.5 0.513
Item 9: do you run out of hypertension pills 1.4 ± 0.5 0.566
Item 10: you skip your hypertension pills 1 to 3
days before you go to the clinic
1.2 ± 0.4 0.712
Item 11: do you miss taking your hypertension pills
when you feel better
1.1 ± 0.3 0.584 0.425
Item 13: do you take someone else’s hypertension pills 1.1 ± 0.3 − 0.757
Item 14: do you miss taking your hypertension
pills when you care less
1.0 ± 0.1 − 0.716
Overall mean score 1.7 ± 0.2
Percentage of explained variance 24.1 16.7 10.8
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Multivariate Logistic Model for Adherence
to Antihypertensive Therapy
A logistic regression analysis was conducted to identify fac-
tors associated with adherence to antihypertensive therapy
(adherence > 80%) (Table 3). A test of the full model against
a constant only model was statistically significant, indicating
that the predictors as a set reliably distinguished between ad-
herence (≥ 80%) and non-adherence to antihypertensive ther-
apy (χ2 = 36.16, p = 0.001 with df = 15).
Nagelkerke’s R2 of 0.35 indicated a relationship between
prediction and grouping by adherence. Prediction success over-
all was 71.7% (60.8% for adherence and 79.7% for non-adher-
ence). The Wald criterion demonstrated that only attendance of
follow-up visits, having a treatment buddy, and missing clinic
appointments made a significant contribution to prediction.
In the multivariate model, patient’s age was not a signifi-
cant predictor for adherence. Several co-variates were identi-
fied as independent predictors for adherence to antihyperten-
sive therapy (Table 3). Ever having missed a clinic appoint-
ment (OR = 0.2, 95% CI 0.1, 0.6), having a support buddy
(OR = 5.4, 95% CI 1.1, 27.6) and always attending follow-up
visits (OR = 3.1, 95% CI 1.1, 8.7) were significant factors for
adherence to antihypertensive therapy.
Discussion
This study aimed to validate the Hill-Bone Scale for assessing
adherence to antihypertensive therapy in the primary health
care in semi-urban settlements of Namibia (Table 2). The
modified 12-item Namibian version of the Hill-Bone compli-
ance scale showed reasonable internal consistence and con-
struct validity of the three sub-scales for use to assess adher-
ence to antihypertensive medication in primary health care in
Namibia (Table 2). Previous studies in PHC settings across
countries including Korea, Persia, Poland, South Africa and
Turkey indicate that the Hill-Bone scale is a reliable and valid
tool to assess adherence to antihypertensive therapy [13, 27,
31–34]. However, the Hill-Bone scale should be validated in
the urban PHC settings in Namibia before it is universally
used throughout Namibia for measurement of adherence.
This study also assessed the level and factors that may affect
adherence to antihypertensive therapies as well as lifestyle and
other factors that may impact on achieving control of blood
pressure (Tables 1 and 3). In this study, no patient had perfect
adherence to antihypertensive therapy, and over half (58%) of the
patients had adherence levels less than the designated threshold
of 80% [6, 26, 30]. This is lower than studies in South Africa and
Zambia [22, 35], but comparable to other countries including
Kenya and Korea [13, 36–38]. Any differences may be due to
the different study and culture settings, patient characteristics, as
well as sub-scales of the Hill-Bone scale used to assess compli-
ance. In addition, we are more likely to see non-adherent patients
referred to hospitals for the management of complications and/or
investigations, adversely affecting documented adherence rates.
The study found a positive association between visit atten-
dance and adherence to antihypertensive therapy, similar to
other studies [6, 39]. A multivariate logistic analysis indicated
that having social support, regular attendance of follow-up visits
and never missed a clinic appointment were significant predic-
tors of adherence to antihypertensive medication (Table 3).
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Similar studies have reported the lack of treatment support
buddies and/or a spouse as an important risk factor for non-
adherence to antihypertensive medication, particularly among
the elderly [6, 37, 40]. There will be further ongoing research-
investigating issues such as social support in more depth given
its importance in helping to improve future adherence rates.
Despite the fact that most patients often forget to make
a suitable appointment date for the next clinic (Hill-Bone
score mean 3.9 out of 4), missing of appointments was com-
mon (Table 2). In this study, the majority of patients missed at
least one or more of their follow-up visit. The main reasons for
missing follow-up visits were the lack of transport to the fa-
cility, forgetting the appointment dates, work-related pressures
and feeling unwell.
The discrepancy between knowing the date for the next visit
(appointment date) and actually turning up for an appointment
may require added benefits or incentives for attending and/or the
availability of a system to track the patients. There may also be a
need for a reminder system for clinic appointments and refill
appointments in Namibia to enhance adherence to visits and
treatment. In addition, critically looking at issues such as trans-
port, where this is a concern, as well as flexibility of opening
hours of the PHCs given the high prevalence of hypertension in
Namibia and the fact that there is currently no co-payment for
these medicines. Longer distance also negatively impacted on
adherence rates in a study in Northwest Ethiopia, especially
when it was accompanied by poor infrastructure [41].
Extending available personnel and systems to manage these
patients could help, which could include additional nurses and
pharmacists [42, 43].
In this study, despite approximately eight out of ten patients
having a literacy level of primary education and above, adher-
ence to antihypertensive therapy was still sub-optimal. This is in
contrast with previous studies in Africa and elsewhere that have
associated non-adherence to antihypertensive therapy to low-
literacy levels defined by Saounatsou as years of schooling and
Yiannakopoulou et al. as below lyceum or university [6, 44, 45].
This discrepancy may be in part explained by the fact that less
than half of the patients in this study were literate about the
consequences of uncontrolled high blood pressure (Table 1).
However, we did not find any significant association between
adherence and literacy on antihypertensive medication
(p = 0.594). The non-adherence to antihypertensive therapy in
this study may also though be due in part to the low socioeco-
nomic status of the study population, which may negatively im-
pact on health care seeking behaviours especially if there are
transport difficulties [41]. The limited capacity for monitoring
adherence to antihypertensive therapy at the PHC clinics in
Namibia may also negatively impact on adherence despite uni-
versal access.
Our findings are different from those of other studies that have
associated adherence to the level of education, complications of
hypertension, antihypertensive dosage regimen, concomitant
chronic disease states, patients’ age, access to medicines, quality
of care and attendance of follow-up visits [6, 39, 46–49]. These
Table 3 Multivariate logistic model for adherence to antihypertensive
therapy
Covariates Adjusted OR (95% CI) p value
PHC distance from state hospital
< 3 km 1.0
> 3 km 0.8 (0.3, 2.3) 0.717
Patient’s age (years)
1.0
2.6 (0.9, 7.7) 0.084
Patient’s sex (years)
1.0
1.2 (0.5, 3.2) 0.703
Secondary education level
Yes 1.0
No 0.7 (0.3, 2.0) 0.515
Employment status
Employed 1.0
Unemployed 1.1 (0.4, 2.8) 0.903
Marital status
Married 1.0
Single 1.9 (0.7, 4.9) 0.208
Years with hypertension (years)
< 5 years 1.0
> 5 years 0.6 (0.2, 1.6) 0.332
Chronic co-morbidity
Yes 1.0
No 1.0 (0.4, 2.5) 0.923
Received adequate refill on last visit
Yes 1.0
No 0.8 (0.2, 2.7) 0.682
Adequately informed on use of medicines
Yes 1.0
No 1.8 (0.5, 6.4) 0.401
Knows consequences of hypertension
No 1.0
Yes 0.7 (0.3, 2.0) 0.534
Always attends follow-up visits
No 1.0
Yes 3.1 (1.1, 8.7) 0.030*
Has support buddy
No 1.0
Yes 5.4 (1.1, 27.6) 0.045*
Missed a clinic appointment
Never 1.0
Ever 0.2 (0.1, 0.6) 0.002*
Constant 0.5 0.613
Variable(s) entered on step 1: treatment support buddy, always attends
visits, age of patient, ever missed clinic appointment
Cardiovasc Drugs Ther
differences may be due to the fact that our study was conducted
among a homogenous population – among people of a low so-
cioeconomic status and at primary level of care. Two thirds of the
respondents in this study were from one ethnic group,
Oshiwambo, and adherence may be influenced by the local cul-
ture. A number of studies have been conducted at the hospital
level, which usually have more diverse populations of respon-
dents and prescribers. A homogenous population is more likely
to have similar behaviours compared to a heterogeneous one.We
plan to confirm this in future studies.
There was also no significant association between adher-
ence and patients’ demographic characteristics including pa-
tient’s age, sex, employment status, education level as well as
literacy on hypertension therapy (Table 3) and having another
chronic co-morbidity such as HIV/AIDS or diabetes alongside
hypertension. No association with concomitant chronic illness
such as HIV/AIDS is an interesting finding, especially as con-
comitant HIV/AIDs will appreciably increase the pill burden,
which is known to adversely affect adherence rates [48, 50].
This may be because HIV/AIDS patients are more regularly
monitored and counselled about medication adherence, which
itself may influence adherence rates across disease areas de-
spite appreciably increasing the number of pills taken each
day. We have seen this in other NCD disease areas in Africa
such as diabetes whereby adherence rates may in fact be in-
creased if patients have concomitant HIV. This may be be-
cause these co-morbid patients feel better cared for than those
with only hypertension, positively impacting on adherence
rates in practice [51]. We plan to follow this up in future
research studies as the rationale will provide additional guid-
ance on ways to further improve adherence to antihyperten-
sive medicines in Namibia.
Limitations
We accept this study has a number of limitations. The principal
one includes the limited sample of hospitals included (four
clinics in the informal settlements of Windhoek, the capital city
of Namibia) and the non-inclusion of the three clinics in the
central business district of Windhoek. We are currently
conducting a similar study among the remaining PHC facilities
in centralWindhoek and aim to compare the findings from these
two studies. Nevertheless, we believe that the findings of this
study alone are important in providing evidence which can
guide efforts to improve adherence to antihypertensive therapy
among patients of low social economic status in Namibia.
Conclusions
The modified 12-item Namibian version of the Hill-Bone
compliance scale is a reliable and valid tool for assessing
adherence to antihypertensive therapy in semi-urban settings
of Namibia.
There is currently sub-optimal adherence to antihypertensive
therapy among patients attending the PHC facilities, which is a
concern. Irregular attendance of follow-up visits, lack of treat-
ment support and missing appointments are important risk fac-
tors for adherence to antihypertensive medication in our study.
Distance was also important in the bivariate but not multivariate
analysis. As a result, there is need for standard packages in
antihypertensive therapy at PHCs, as well as a system tomonitor
and remind patients of their follow up-visits, to address current
concerns. This could involve mHealth techniques and mobile
reminder systems in the future. There is also a need to build
capacity to initiate and monitor antihypertensive therapy at the
PHC level. This may mean making PHCs becoming more flex-
ible when they can see patients as well as looking at using other
professionals in care delivery such as community pharmacists.
Incentives could potentially be offered to patients to ad-
dress identified barriers. Assessing the rationale behind simi-
lar medication adherence rates between hypertensive patients
with and without HIV/AIDs is also likely to help with
programmes to improve future adherence rates. Alongside,
this is assessing the actual impact of these activities on im-
proving long-term blood pressure control.
The outcomes of this study will inform the development of
appropriate strategies in PHCs in Namibia, integrating treatment
literacy services, treatments and outcomes at all or specific
points of care. Potential target areas include counseling, pre-
scribing, dispensing and follow-up of patients. Ultimately, pa-
tients should be empowered to monitor their own clinical out-
comes and adherence to antihypertensive therapy. In addition,
investigating further issues such as transport and what can be
learnt from patients jointly having hypertension and HIV, given
the appreciable burden of both in Sub-Saharan countries. Once
underway, seek to potentially instigate screening programmes to
reduce the morbidity, mortality and costs associated with hyper-
tension in Namibia given the likely extent of undiagnosed hy-
pertension. This will help Namibia achieve SDG 3.4.
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Appendix A
Please ( ) where appropriate
QUESTIONNAIRE
No:
QUESTIONAIRE
Date: …………………………………
Hello. I would like to thank you for taking time to complete this questionnaire. This is to help
me with my university research on Medication Adherence among Hypertensive Patients
attending Four Clinics in Windhoek for Follow-ups. I therefore implore you to please answer
truthfully so that the results of the research will be of sound quality. All the information will
be kept confidential. If you have any questions while filling in this questionnaire, please ask
the questionnaire administrator. Thank you.
Section A: DEMOGRAPHIC DATA
1. Age (at last birthday)
2. Sex Male Female 
3. Highest level of  Education reached:
a. Tertiary Education
b. Secondary Education 
(grade 8-12)
c. Primary Education (grade 
1-7)
d. None
4. Occupation
a. Student
b. Employed
c. Self-employed
d. Unemployed
5.Marital status
Single
Married
In a relationship
6.Ethnicity
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SECTION B: Personal Medical History
1. When were you diagnosed with High blood pressure? (year) ___________________
2. Do you have any other chronic illness(es)___________________________________
3. If yes, please mention it (them) ___________________________________________
4. At your last visit at the clinic for your high blood pressure follow-up, did you receive enough 
medication to last you until your next visit? 
____________________________________________________________________
5. Did your nurse or doctor tell you when, how and why you need to take your high blood 
pressure medication every time you are supposed to? 
____________________________________________________________________
6. Do you know what might happen if you do not take your medication every time you are 
supposed to? __________________________________________________________
7. Do your friends and family encourage you to take your medication? 
_____________________________________________________________________
8. Do your friends and family accompany you to the clinic for follow-ups? 
_____________________________________________________________________
9. Do you always go to your follow-ups on the days you are supposed to? 
____________________________________________________________________
10. If not, please say why?  -
__________________________________________________________________
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SECTION C: Hill-Bone Compliance to High Blood Pressure Therapy Scale
(Please answer the following questions in the table below, by ticking appropriately.)
1. How often do you forget to take your hypertension medicine? 
None of the time Some of the time Most of the time All the time
2. How often do you decide not to take your hypertension medicine? 
None of the time Some of the time Most of the time All the time
3. How often do you eat salty food? 
None of the time Some of the time Most of the time All the time
4. How often do you put salt, Fondor or Aromat on your food before you eat it? 
None of the time Some of the time Most of the time All the time
5. How often do you eat fast food (KFC, kapana, fat cook, fish and chips)? 
None of the time Some of the time Most of the time All the time
6. How often do you forget to make the next clinic appointment before you leave the clinic? 
None of the time Some of the time Most of the time All the time
7. How often do you miss scheduled appointments?
None of the time Some of the time Most of the time All the time
8. How often do you leave the dispensary before obtaining your prescribed pills (due to long 
line, closure of clinic, forgetting)?
None of the time Some of the time Most of the time All the time
9. How often do you run out of hypertension pills? 
None of the time Some of the time Most of the time All the time
10. How often do you skip your hypertension pills 1 to 3 days before you go to the clinic?
None of the time Some of the time Most of the time All the time
11. How often do you miss taking your hypertension pills when you feel better?
None of the time Some of the time Most of the time All the time
12. How often do you miss taking your hypertension pills when you feel sick? 
None of the time Some of the time Most of the time All the time
13. How often do you take someone else’s hypertension pills?
None of the time Some of the time Most of the time All the time
14. How often do you miss taking your hypertension pills when you care less?
None of the time Some of the time Most of the time All the time
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